Connacht Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Connacht Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,798	Closed	-$246K	–	101
2023 Q2	$246K	Buy	6,798 +804	+13%	+$33.1K	0.34%	82
2023 Q1	$223K	Sell	5,994 -1,141	-16%	-$51.3K	0.1%	127
2022 Q4	$323K	Buy	7,135 +3,960	+125%	+$256K	0.15%	91
2022 Q3	$222K	Sell	3,175 -212	-6%	-$15.7K	0.16%	111
2022 Q2	$227K	Buy	3,387 +69	+2%	+$4.39K	0.1%	133
2022 Q1	$273K	Sell	3,318 -3,138	-49%	-$321K	0.14%	114
2021 Q4	$947K	Buy	+6,456	New	+$1M	0.92%	42

Other funds holding MRTX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connacht Asset Management's MRTX Position: Q3 2023 in Review

Connacht Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 6,798 shares — an estimated $246K sold.

Connacht Asset Management first reported a position in MRTX in Q4 2021 and held it in 7 quarters. The position peaked at $947K in Q4 2021. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Connacht Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Connacht Asset Management sold 6,798 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $246K.
Connacht Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Connacht Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $947K in Q4 2021.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.